Physician profile
Parag J Patel
NPI 1245233345
$171,361.68
in general payments reported to CMS, 2019-2025
12 companies · $49K in 2025
The $49K reported for 2025 was more than what 99% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $544 · 2021: $81.10 · 2022: $395 · 2023: $34K · 2024: $87K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $128K · Travel and Lodging: $37K · Food and Beverage: $4,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $128,380.00 |
| Travel and Lodging | $37,365.57 |
| Food and Beverage | $4,366.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $169,794.60 | 2023-2025 | Brixadi |
| Mdd US Operations, LLC | $548.91 | 2019-2020 | |
| Indivior INC. | $344.53 | 2019-2022 | |
| Allergan, INC. | $192.43 | 2022 | |
| Merz North America, INC. | $161.52 | 2024 | |
| Uswm, LLC | $81.10 | 2021 | |
| Alkermes, INC. | $63.01 | 2019-2022 | |
| Galderma Laboratories, L.P. | $58.99 | 2025 | Dysport |
| Abbvie INC. | $54.48 | 2023-2025 | |
| Revance Therapeutics, INC. | $25.45 | 2025 | Daxxify |
| Otsuka America Pharmaceutical, INC. | $19.16 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.50 | 2025 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.